In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Thermo Fisher’s current price exceeds its PERT-weighted fair value by 24.6%, indicating potential overvaluation despite strong profitability and liquidity scores. Monte Carlo analysis shows high volatility and 77.8% downside risk below the current price, reflecting significant valuation uncertainty. Valuation methods diverge widely, suggesting varied market perspectives on growth and risk.